Updates to the Management of Cutaneous Melanoma

The systemic therapeutic landscape for cutaneous melanoma continues to evolve, with numerous diverse options currently available. Several clinical trials have resulted in approvals from the FDA and subsequent revisions to the NCCN Guidelines, which reflect the most up-to-date, evidence-based data relating to the evaluation and management of these malignant neoplasms. Combination checkpoint blockades, anti–PD-1 and anti–CTLA-4 monotherapies, and mutation-directed therapies are among the NCCN-recommended approaches across the neoadjuvant, first-line, and later-line settings. Tumor-infiltrating lymphocyte therapy, a recent addition in the later-line setting, may mark a new era in the management of metastatic disease.